XenoPort to Release First Quarter Financial Results on May 6, 2015
April 28 2015 - 01:00PM
Business Wire
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will
release its first quarter financial results on May 6, 2015 at
approximately 4:30 p.m. Eastern Time. The company will host a
conference call at 5:00 p.m. Eastern Time that same day to provide
a summary of its financial results and general business updates. A
replay of the call will be available for one week following the
event.
To access the conference call via the Internet, go to
www.XenoPort.com. Please join the call at least 15 minutes prior to
the start to ensure time for any software downloads that may be
required.
To access the live conference call via phone, dial
1-888-275-3514. International callers may access the live call by
dialing 706-679-1417. The reference number to enter the call is
22550328.
The replay of the conference call may be accessed that same day
after 8:00 p.m. Eastern Time, via the Internet, at
www.XenoPort.com, or via phone at 1-855-859-2056 for domestic
callers, or 404-537-3406 for international callers. The reference
number to enter the replay of the call is 22550328.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on
developing and commercializing a portfolio of internally discovered
product candidates for the potential treatment of neurological
disorders. XenoPort is currently commercializing HORIZANT®
(gabapentin enacarbil) Extended-Release Tablets in the United
States and developing its novel fumaric acid ester product
candidate, XP23829, as a potential treatment for patients with
moderate-to-severe chronic plaque-type psoriasis and potentially
for relapsing forms of multiple sclerosis. REGNITE® (gabapentin
enacarbil) Extended-Release Tablets is being marketed in Japan by
Astellas Pharma Inc. XenoPort has entered into a collaboration with
the National Institute on Alcohol Abuse and Alcoholism for the
potential development of HORIZANT as a treatment for AUD and has
granted exclusive world-wide rights for the development and
commercialization of its clinical-stage oral product candidate,
arbaclofen placarbil, to Indivior PLC for all indications.
XenoPort's pipeline of product candidates also includes a potential
treatment for patients with idiopathic Parkinson's disease.
HORIZANT, REGNITE and XENOPORT are registered trademarks of
XenoPort, Inc.
XNPT2F
XenoPort, Inc.Jackie Cossmon, 408-616-7295ir@XenoPort.com
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Mar 2023 to Mar 2024